Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (boostrix®): A review of its properties and use as a single-dose booster immunization

Drugs

Volumn 72, Issue 13, 2012, Pages 1765-1791

  McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Diphtheria; DTaP vaccine; Elderly; Pertussis; Tetanus

Indexed keywords

ALUMINUM; ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; TETANUS TOXOID;

ANOREXIA; ANTIBODY PRODUCTION; DIPHTHERIA; DROWSINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEVER; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; PERTUSSIS; REVIEW; SIDE EFFECT; TETANUS; UNITED STATES; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; DIPHTHERIA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNIZATION, SECONDARY; TETANUS; VACCINES, ACELLULAR; VACCINES, COMBINED; WHOOPING COUGH;

EID: 84865642170     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209630-000000000-00000     Document Type: Review

References (98)

1. Di Pasquale A, Wolter J, Schuerman L. Management of pertussis in adolescents and adults: the role of a reducedantigen content combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine. J Prev Med Hyg 2005 Mar; 46 (1):33-41 (Pubitemid 40547111)
2. World Health Organization. World health statistics 2012; part III global health indicators [online]. Available from URL: http://www.who.int/healthinfo/ EN-WHS2012-Part3.pdf [Accessed 2012 May 30]
3. Halperin SA, Scheifele D, De Serres G, et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine 2012 Jan 20;30(5):974-82
4. World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010 Oct. 1;85(40):385-400
5. Hellenbrand W, Beier D, Jensen E, et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis 2009 Feb. 25;9:22
6. Yeh SH, Mink CM. Shift in the epidemiology of pertussis infection: an indication for pertussis vaccine boosters for adults? Drugs 2006;66(6):731-41 (Pubitemid 43765221)
7. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011 Oct. 21;60(41):1424-6
8. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007 Apr; 26 (4):293-9 (Pubitemid 46596651)
9. Forsyth KD, Wirsing von Konig CH, Tan T, et al. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007 Mar. 30;25(14):2634-42 (Pubitemid 46400927)
10. Moreno-Pérez D, Álvarez García FJ, Aristegui Fernández J, et al. Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations. An Pediatr (Barc) 2012 Jan; 76 (1):43e1-23
11. National Health and Medical Research Council. The Australian immunisation handbook 9th edition 2008: pertussis [online]. Available from URL: http://www.immunise.health.gov. au/internet/immunise/publishing.nsf/Content/ Handbook-pertussis [Accessed 2012 Jul. 30]
12. Schmitt HJ, Von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996 Jan 3;275(1):37-41 (Pubitemid 26004253)
13. Centers for Disease Control and Prevention. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000 Nov. 17;49(RR-13):1-8
14. EUVAC. NET. Childhood vaccination schedule [online]. Available from URL: http://www.euvac.net/graphics/euvac/vaccination/unitedkingdom.html [Accessed 2012 Jul. 30]
15. GlaxoSmithKline. GlaxoSmithKline receives FDA approval for BOOSTRIX to help prevent whooping cough in adults 65 years and older [media release]. 2011 Jul. 8 [online]. Available from URL: http://us.gsk.com/html/medianews/ pressreleases/2011/2011-pressrelease-521635.htm
16. ™). Drugs 2003;63(13):1407-13 (Pubitemid 36776094)
17. ™): a review of its use as a single-dose booster immunization. Bio-Drugs 2006;20(6):371-89 (Pubitemid 46091590)
18. ®): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US. BioDrugs 2009;23(4):253-67
19. ™). Hum Vaccin 2010 March; 6 (3):263-9
20. Huang LM, Chang LY, Tang H, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheriatetanusacellular pertussis vaccine in healthy Taiwanese children and adolescents. J Adolesc Health 2005 Dec; 37 (6):517.e1-5
21. Kosuwon P, Warachit B, Hutagalung Y, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003 Oct. 1;21(27-30):4194-200 (Pubitemid 37130264)
22. Zepp F, Cheuvart B, Wolter JM. Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (DTPA) in pre-school-aged children [abstract no. 281.00 plus poster]. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases; 2003 Apr. 9-11; Taormina
23. Cheuvart B, Burgess M, Zepp F, et al. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 2004 Dec. 2;23(3):336-42 (Pubitemid 39463052)
24. Pichichero ME, Blatter MM, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006 Apr; 117 (4):1084-93 (Pubitemid 46071499)
25. Theeten H, Van Damme P, Hoppenbrouwers K, et al. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine 2005 Feb. 10;23(12):1515-21 (Pubitemid 40164712)
26. Abarca K, Valdivieso F, Potin M, et al. Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine (dTpa) in 10 to 11 years old children and in adults [in Spanish]. Rev Med Chil 2002 May; 130 (5):502-10
27. Knuf M, Zepp F, Meyer C, et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 2006 Mar. 15;24(12):2043-8 (Pubitemid 43255145)
28. Southern J, Andrews N, Burrage M, et al. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 2005 May 31;23(29):3829-35 (Pubitemid 40704747)
29. Tran Minh NN, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999 Dec; 104(6):e70
30. ™) is immunogenic and well tolerated in adults. Vaccine 2010 Dec. 10;29(1):45-50
31. Mertsola J, Van der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010 Sep. 15;51(6):656-62
32. Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 2009 Jan 29;27(5):765-72
33. Chan SH, Tan P T N, Han HH, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheriatetanusacellular pertussis vaccine as a single-dose booster in Singaporean adults. Singapore Med J 2006 Apr; 47 (4):286-90
34. Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000 Nov. 8;19(6):628-36
35. Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanusacellular pertussis (dTpa) vaccine in adults. Vaccine 2000 Apr; 18 (20):2075-82 (Pubitemid 30129096)
36. Hoel T, Wolter JM, Schuerman LM. Combined diphtheriatetanuspertussis vaccine for tetanus-prone wound management in adults. Eur J Emerg Med 2006 Apr; 13 (2):67-71 (Pubitemid 44153114)
37. ®): results of two randomized trials. Vaccine 2012 Feb. 21;30(9):1721-8
38. GlaxoSmithKline. Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed): US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us-boostrix.pdf [Accessed 2012 Jul. 30]
39. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010 Jul; 17 (7):1055-65
40. Pichichero ME, Anderson EL, Rennels MB, et al. Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four-to six-year-olds. Pediatr Infect Dis J 2001 Apr; 20 (4):427-33 (Pubitemid 32294754)
41. Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998 Dec; 16 (20):1907-16 (Pubitemid 28473934)
42. Cherry JD, Gornbein J, Heininger U, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998 Dec; 16 (20):1901-6 (Pubitemid 28473933)
43. Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J 2011 Dec; 30(12):e225-34
44. Weston WM, Chandrashekar V, Friedland LR, et al. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when coadministered with influenza vaccine in adults. Hum Vaccin 2009 Dec; 5 (12):858-66
45. Weston WM, Friedland LR, Wu X. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine 2011 Jan 29;29(5):1017-22
46. Zepp F, Habermehl P, Knuf M, et al. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine 2007 Jul. 20;25(29):5248-52 (Pubitemid 46977539)
47. Vergara R, Tregnaghi M, Ussher J, et al. Reduced- antigencontentdiphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 2005 Jun; 164 (6):377-82 (Pubitemid 40869012)
48. Edelman KJ, He Q, Makinen JP, et al. Pertussis-specific cellmediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 2004 Jul. 15;39(2):179-85 (Pubitemid 38971487)
49. Edelman K, He Q, Makinen J, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007 May 15;44(10):1271-7 (Pubitemid 46717287)
50. ™ in healthy adults, 10 years after previous booster vaccination [online]. Available from URL: http://www.gsk-clinicalstudyregister. com/result-detail.jsp?protocolId=113055&studyid=9E98A336-4BF2-40A6-93F3- 3ACC952CEE85&compound= Combined+Reduced+Antigen+Content+Diphtheria%2C+Tetanus%2C+Acellular+Pertussis+V accine [Accessed 2012 May 16]
51. McIntyre PB, Turnbull FM, Egan AM, et al. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 2004 Dec. 2;23(3):380-5 (Pubitemid 39467727)
52. McIntyre PB, Burgess MA, Egan A. Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years postvaccination. Vaccine 2009 Feb. 11;27(7):1062-6
53. Weston W, Messier M, Friedland LR, et al. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine. Vaccine 2011 Nov. 3;29(47):8483-6
54. ®) in adults 55 years of age and over: a subanalysis of four trials. Vaccine 2011 Aug. 11;29(35):5932-9
55. Leuridan E, Hens N, Peeters N, et al. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011 Jul; 30 (7):608-10
56. GlaxoSmithKline. Study no. 263855/014 (dTpa-014). A phase III, double-blind, randomized, single vaccination study of SmithKline Beecham Biologicals' reduced antigen content diphtheria-tetanus-acellular pertussis and combined diphtheria-tetanus-whole cell Bordetella pertussis vaccines in healthy children, aged 4 to 6 years [online]. Available from URL: http://www.gsk- clinicalstudyregister.com/result-detail.jsp?protocolId=263855%2F014&studyId= 3AAC767A-F8CE-41AB-8E5F-AC3EFC886B9C&compound= Combined+Reduced+Antigen+Content+Diphtheria%2C+Tetanus%2C+Acellular+Pertussis+V accine [Accessed 2012 Apr. 26]
57. ™ in adults aged 65 years or older [online]. Available from URL: http://www.gsk-clinicalstudyregister.com/result-detail.jsp?protocolId= 111413&studyid=7256C088-02D3-4BEA-BD29-ADF1A547F4CC&compound= Combined+Reduced+Antigen+Content+Diphtheria%2c+Tetanus%2c+Acellular+Pertussis+V accine [Accessed 2012 May 2]
58. Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22, 505 infants. J Pediatr 1996;129(5):695-701 (Pubitemid 27498279)
59. Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus- acellular pertussis vaccine in adults. Vaccine 2004 Jan 2;22(3-4):305-8 (Pubitemid 37510259)
60. Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Ped Infect Dis J 2009 Feb; 28 (2):152-3
61. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005 Oct. 13;353(15):1555-63 (Pubitemid 41434634)
62. Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010 Aug. 1;51(3):315-21
63. Zepp F, Knuf M, Habermehl P, et al. Safety of reducedantigencontent tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussiscontaining vaccine. J Pediatr 2006 Nov; 149 (5):603-10
64. ™) in pre-school Indian children. Indian Pediatr 2007 Jun; 44 (6):421-4 (Pubitemid 46997983)
65. Quinn P, Gold M, Royle J, et al. Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old. Vaccine 2011 Jun. 6;29(25):4230-7
66. Moro PL, Yue X, Lewis P, et al. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010. Vaccine 2011 Nov. 21;29(50):9404-8
67. Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States Health Maintenance Organization. Pediatr Infect Dis J 2010 Jul; 29 (7):613-7
68. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 2009 Jul. 9;27(32):4257-62
69. Scheifele DW, Halperin SA, Ochnio JJ, et al. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 2005 Dec; 24 (12):1059-66 (Pubitemid 43011060)
70. Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009 May; 5 (5):315-21
71. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011 Jan 14;60(1):13-5
72. Fisman DN, Tang P, Hauck T, et al. Pertussis resurgence in Toronto, Canada: a population-based study including testincidence feedback modeling. BMC Public Health 2011;11:694
73. Paisley RD, Blaylock J, Hartzell JD. Whooping cough in adults: an update on a reemerging infection. Am J Med 2012 Feb; 125 (2):141-3
74. Poolman JT, Hallander H, Halperin SA. Pertussis vaccines: where to now? Expert Rev Vaccines 2011 Nov; 10 (11):1497-500
75. Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005 May; 24 Suppl. 5:S58-61 (Pubitemid 40676539)
76. De Vries R, Kretzschmar M, Schellekens JF, et al. Costeffectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS One 2010 Oct; 5(10):e13392
77. Public Health Agency of Canada. Canadian immunization guide: seventh edition 2006 [online]. Available from URL: http://www.phac-aspc.gc.ca/publicat/ cig-gci/index-eng.php [Accessed 2012 Jul. 30]
78. New Zealand Ministry of Health. Immunisation handbook [online]. Available from URL: http://www.health.govt.nz/publication/immunisation-handbook-2011 [Accessed 2012 Jul. 30]
79. Committee on Infectious Diseases. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Pediatrics 2011 Oct; 128 (4):809-12
80. Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of pertussis. Science 2010 Nov. 12;330(6006):982-5
81. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004 Nov; 23 (11):985-9 (Pubitemid 40824285)
82. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998 May; 17 (5):412-8 (Pubitemid 28232866)
83. Skowronski DM, Janjua NZ, Tsafack EP, et al. The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clin Infect Dis 2012 Feb. 1;54(3):318-27
84. Halperin BA, Morris A, Mackinnon-Cameron D, et al. Kinetics of the antibody response to tetanus-diphtheriaacellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011 Nov; 53 (9):885-92
85. Ausiello CM, Lande R, Urbani F, et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis 2000 Jun; 181 (6):1989-95 (Pubitemid 30416162)
86. Marshall HS, Gold MS, Gent R, et al. Ultrasound examination of extensive limb swelling reactions after diphtheriatetanusacellular pertussis or reduced-antigen content diphtheria-tetanus-acellular pertussis immunization in preschoolaged children. Pediatrics 2006 Oct; 118 (4):1501-9 (Pubitemid 46393796)
87. Huber BM, Goetschel P. Extensive limb swelling after vaccination. J Pediatr 2011 Jun; 158 (6):1033
88. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin Infect Dis 2004 Dec. 15;39(12):1802-9 (Pubitemid 39657260)
89. Girard DZ. The distribution over time of costs and social net benefits for pertussis immunization programs. Int J Health Care Finance Econ 2010 Jan; 10 (1):1-27
90. Caro JJ, Getsios D, El-Hadi W, et al. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 2005 May; 24 (5 Suppl.): S75-82 (Pubitemid 40676542)
91. Iskedjian M, Walker JH, Hemels ME. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 2004 Oct. 22;22(31-32):4215-27 (Pubitemid 39330343)
92. Iskedjian M, Walker JH, De Serres G, et al. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Quebec, Canada. Paediatr Drugs 2005;7(2):123-36 (Pubitemid 40733722)
93. Rozenbaum MH, De Cao E, Postma MJ. Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine. Epub 2012 Jun. 27
94. Coudeville L, Van Rie A, Getsios D, et al. Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One 2009 Jul. 16;4(7):e6284
95. Lee GM, Riffelmann M, Wirsing von Konig CH. Costeffectiveness of adult pertussis vaccination in Germany. Vaccine 2008 Jul. 4;26(29-30):3673-9
96. Lee GM, Murphy TV, Lett S, et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 2007 Mar; 32 (3):186-93
97. Westra TA, De Vries R, Tamminga JJ, et al. Costeffectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther 2010 Aug; 32 (8):1479-95
98. Purdy KW, Hay JW, Botteman MF, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004 Jul. 1;39(1):20-8(Pubitemid 38879544)